Weekly contraception with mifepristone

Pei, Kaiyan; Xiao, Biao; Jing, Xiaoping; Lu, Shengqun; Ling, Wei; Zhao, Heng

doi:10.1016/j.contraception.2006.08.013

Cited by 30 publications

(13 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ovulation suppression in studies with 10, 25, and 50 mg mifepristone was inconsistent [39,66,67]. Spitz and Chen et al found only partial suppression of progesterone but Pei et al reported no pregnancies during the 6-month pilot clinical trial totaling 456 cycles using 50 mg dose weekly for six cycles (456 cycles) [67].…”

Section: Mifepristone For Ongoing Contraceptionmentioning

confidence: 97%

Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development

Nelson¹

2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

Of all the investigational hormone agonist/antagonists, SPRMs have demonstrated the greatest potential as ongoing female contraceptives. They have the ability to suppress ovulation after initiation of the luteinizing hormone (LH) surge without affecting ovarian production of estrogen or inducing any significant metabolic changes. SPRMs may well be able to provide longer term contraception as oral agents, vaginal rings, and perhaps even intrauterine devices. UPA has the greatest promise. Current research needs to be expanded.

show abstract

Section: Mifepristone For Ongoing Contraceptionmentioning

confidence: 97%

Investigational hormone receptor agonists as ongoing female contraception: a focus on selective progesterone receptor modulators in early clinical development

Nelson¹

2015

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

“…Daily low doses of mifepristone (≥2 mg/day) inhibit ovulation, prevent secretory transformation of the endometrium and induce amenorrhea [87][88][89]. Pei et al have recently demonstrated that weekly administration of mifepistone (25 and 50 mg) also inhibited ovulation [90]. This weekly intake may participate in improving compliance.…”

Section: Non-ee-containing Compoundsmentioning

confidence: 94%

Third-generation oral contraceptives: future implications of current use

Ouzounian¹,

Verstraete²,

Chabbert-Buffet

2008

Expert Review of Obstetrics & Gynecology

View full text Add to dashboard Cite

Third-generation oral contraceptives are an association of low-dose ethinyl estradiol and potent testosterone-derived progestins, developed in order to improve general and vascular tolerance. They are highly efficient and well tolerated by most users. Their extensive use has provided different key information: oral contraceptives (as well as non-oral ethinyl estradiolcontaining contraceptives) can be used in women under the age of 35 years with wellcontrolled metabolic risk factors and high familial risk of breast cancer. On the other hand, ethinyl-estradiol containing contraceptives are not indicated in women with a high risk of deep venous thrombosis, or noncontrolled metabolic and vascular risk factors (including being over the age of 35 years or cigarette smoking), or with a history of breast cancer. Progestin-only contraception is not well tolerated owing to bleeding. Future hormonal contraception for women with a high vascular risk may contain nontestosterone-derived progestins and 17β estradiol, or antiprogestins.

show abstract

“…In the first case, in an open-label trial of 76 women, a weekly dose of 25 or 50 mg was given. No pregnancies occurred during 456 women-months [52]. In another randomized, controlled, double-blinded trial of 96 women, either 5 mg of mifepristone or 30 mg of levonorgestrel were given daily for 24 weeks.…”

Section: Mifepristonementioning

confidence: 98%